BioAge Labs, Inc. Common Stock (BIOA)
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to target aging and age-related diseases. Leveraging insights from aging biology, it aims to extend healthspan and improve quality of life by identifying and modulating molecular pathways involved in aging processes.
Company News
BioAge Labs initiated a Phase 1 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor targeting obesity treatment, with potential to address neuroinflammation and complement existing therapies like GLP-1 agonists.
BioAge Labs reported Q2 2025 earnings with first collaboration revenue of $2.41 million, increased R&D expenses, and continued development of obesity and metabolic disease treatments, including BGE-102 and APJ agonist programs.
BioAge Labs, a clinical-stage biopharmaceutical company, announced the closing of its initial public offering and concurrent private placement, raising approximately $238.3 million in gross proceeds.